032sek
-11,7 %
Date:2026-07-09Time:17:29:00Latest report:Q1-2026List:SpotlightTicker:PHAL
Market Cap:23 msekEnterprise Value:26 msekNet Sales:- msekEarnings:-7,22 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,32
MA50:0,14
MA200:0,27
Price/MA200:34,8 %
RSI (14):90,8
Price/MA50:163,5 %

Description

PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Biotechnology